Abstracts Archive - Page 517 of 1683 - ATC Abstracts

2020 American Transplant Congress
Next-Generation Sequencing to Assess Cytomegalovirus Viral Populations During the Course of CMV Infection
G. Elhelou¹, R. Razonable²
¹Medicine, Division of Infectious Diseases and Global Medicine, University of Florida, Gainesville, FL, ²Medicine, Division of Infectious Disease, Mayo Clinic, Rochester, MN
*Purpose: Resistant Cytomegalovirus (CMV) infection has emerged to cause significant impact on morbidity and mortality after solid organ transplantation (SOT). There is limited data on…
2020 American Transplant Congress
Evaluation of an Intervention to Reduce Underdosing of Valganciclovir for Primary Prophylaxis of Cytomegalovirus Infection in Donor Seropositive/Recipient Seronegative Kidney and Liver Transplant Recipients
L. Al Bizri¹, Z. S. Chaudhry², A. Vahia², J. Williams², J. C. Lemos-Ramirez³, B. Summers⁴, A. Patel⁵, S. Nagai⁶, O. Abreu Lanfranco², M. Ramesh², R. Del Busto², G. Alangaden²
¹Internal Medicine, Henry Ford Health System, Detroit, MI, ²Infectious Disease, Henry Ford Health System, Detroit, MI, ³Department of Transplant Infectious Disease, Memorial Regional Hospital, Hollywood, FL, ⁴Central Pharmacy, Henry Ford Health System, Detroit, MI, ⁵Nephrology, Henry Ford Health System, Detroit, MI, ⁶Surgery Transplant, Henry Ford Health System, Detroit, MI
*Purpose: Valganciclovir (VCV) prophylaxis is used to prevent primary cytomegalovirus (CMV) infection in CMV donor seropositive/recipient seronegative (D+/R-) solid organ transplant recipients (SOT). We examined…
2020 American Transplant Congress
Clinical Correlation of Results of s CD4/CD8 Cytomegalovirus Cell Mediated Immunity Test with Incidence of Cytomegalovirus Infection
M. Jorgenson¹, M. Hillis¹, C. Saddler², J. Smith², D. Mandelbrot²
¹UW Health, Madison, WI, ²UWMF, Madison, WI
*Purpose: The purpose of this study was to evaluate the predictive potential of a CD4/CD8 flow cytometric cell mediated immunity (CMI) assay for the development…
2020 American Transplant Congress
Incidence of Oropharyngeal and Esophageal Candidiasis in Adult Kidney Transplant Recipients Receiving Nystatin versus No Prophylaxis
L. Moreno¹, K. Klein¹, C. Long², R. Hall¹, J. Nelson¹
¹Pharmacotherapy and Pharmacy Services, Pharmacotherapy Division, University Health System, The University of Texas Health Science Center at San Antonio, The University of Texas at Austin, College of Pharmacy, San Antonio, TX, ²Pharmacotherapy and Pharmacy Services, Pharmacy Practice, University Health System, University of the Incarnate Word Feik School of Pharmacy, San Antonio, TX
*Purpose: The purpose of this study is to evaluate the need for nystatin prophylaxis for oropharyngeal (OPC) and esophageal Candidiasis (EC) in adult kidney transplant…
2020 American Transplant Congress
Letermovir for CMV Prophylaxis and Treatment of Resistant/ Refractory CMV Disease in Solid Organ Transplant Recipients
M. Miller¹, S. Scherger², E. Benamu², V. Bajrovic², P. Ramanan², N. Madinger², M. Barron², S. Johnson², T. Campbell², A. Gray³, A. Weinberg⁴, M. Abidi²
¹Clinical Pharmacy, University of Colorado Hospital, Aurora, CO, ²Infectious Diseases, University of Colorado Denver School of Medicine, Aurora, CO, ³Pulmonology, University of Colorado Denver School of Medicine, Aurora, CO, ⁴Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO
*Purpose: Letermovir (LMV) is approved for primary cytomegalovirus (CMV) prophylaxis in hematopoietic cell transplant recipients. Current FDA-approved antiviral options are limited to foscarnet and cidofovir…
2020 American Transplant Congress
Brincidofovir for Treatment of Disseminated Human Adenovirus Infection in Pediatric Solid Organ Transplant Recipients
J. Londeree¹, R. Garro¹, R. Romero², R. George¹, P. Winterberg¹, R. Liverman³, A. Serluco³, S. Shin¹, I. Yildirim⁴
¹Pediatric Nephrology, Emory, Atlanta, GA, ²Pediatric Hepatology and Gastroenterology, Emory, Atlanta, GA, ³Pharmacy, Children's Healthcare of Atlanta, Atlanta, GA, ⁴Pediatric Infectious Disease, Emory, Atlanta, GA
*Purpose: Brincidofovir (BCV) is an investigational antiviral drug with potency against Human Adenovirus (HAdV). We describe four cases of disseminated HAdV infection treated with (BCV)…
2020 American Transplant Congress
Outcome of Hepatitis B Virus DNA-Positive Liver Transplantation in Hepatitis B Virus/Hepatitis D Virus Co-Infected Recipient Treated with High Dose Hepatitis B Immune Globulin: A Case Report
M. B. Hammami¹, M. Haris¹, L. Toman¹, N. Danis¹, B. Saberi², E. King³, J. Garonzik-Wang³, B. Philosophe³, A. M. Cameron³, A. Gurakar¹
¹Gastroenterology and Hepatology, Johns Hopkins, Baltimore, MD, ²Gastroenterology and Hepatology, Icahn School of Medicine at Mount Sinai, New York, NY, ³Transplant Surgery, Johns Hopkins, Baltimore, MD
*Purpose: Introduction: While common in Asian countries, liver transplantation (LT) for patients with hepatitis B virus (HBV)/hepatitis D virus (HDV) co-infection is rare in the…
2020 American Transplant Congress
Glecaprevir-Pibrentasvir Effect on Tacrolimus Troughs in Abdominal Transplant Recipients
M. Chunduru, K. Schnelle, H. Winters, O. Witkowsky, L. Von Stein
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Glecaprevir-pibrentasvir (GP) is one of several pangenotypic therapies available for the treatment of hepatitis C. Historical use of ritonavir based hepatitis C therapies increased…
2020 American Transplant Congress
Impact and Outcomes of Primary Cytomegalovirus Infection in Seronegative Abdominal Solid Organ Transplant Recipients of Cytomegalovirus Unexposed Donors (D-/R-)
M. Jorgenson¹, M. Hillis¹, N. Friedlander¹, A. Gracon², D. Yang², G. Leverson², J. Smith², R. Redfield²
¹UWHC, Madison, WI, ²UWMF, Madison, WI
*Purpose: Primary cytomegalovirus infection (CMV) in high risk (D+/R-) abdominal solid organ transplant recipients (aSOTRs) is well described, however there is a paucity of literature…
2020 American Transplant Congress
Waitlist Times, Hospital Length of Stay, and Immediate Post-Operative Outcomes of HCV Positive Donors in HCV Negative Liver and Kidney Transplant Recipients
H. Elbeshbeshy¹, J. M. Ray¹, A. Befeler¹, R. Desai¹, K. Qureshi¹, C. Varma²
¹Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO, ²Surgery, Saint Louis University School of Medicine, St. Louis, MO
*Purpose:Introduction The advent of direct-acting antivirals (DAAs) has significantly changed liver and kidney transplantation for patients with chronic hepatitis C (HCV) infection. Successful and relatively…